Total product sales increased year-over-year with 29% to EUR 24.2m in 2019 (EUR 18.8m in 2018), as
a consequence of higher Idylla™ cartridge sales (year-over-year growth of 23%) as well as Idylla™
platform sales (year-over-year growth of 49%).
Total operating income amounted to EUR 37.7m in 2019, representing a year-over-year growth of
32% as a result of higher Idylla™ product sales, collaboration revenues (49% year-over year
growth) and service revenues, partially offset by lower grant income.
Biocartis’ cash position as per 31 December 2019 amounted to EUR 178.7m compared to EUR 63.5m
as per 31 December 2018.
Main shareholders:
A: Invesco Ltd.(1): 12.4%
B: Johnson & Johnson Innovation – JJDC, Inc.(2): 9.7%
C: Debiopharm Innovation Fund S.A.(3): 4.9%
D: ParticipatieMaatschappij Vlaanderen NV (Flemish Region)(4): 4.2%
E: Other institutional and retail investors 68.9%
|
Thread abonnieren
